
    
      This was a phase III, randomized, assessor-blinded, parallel-arm, multicenter, study in
      Japanese patients. Patients, who signed an informed consent and fulfilled all screening
      criteria, were randomized in a 1:1:1 ratio to one of the following 3 treatment groups: "FE
      999169 Split Dosing Schedule", "FE 999169 Day Before Dosing Schedule" and " Niflec On the Day
      Dosing Schedule" in subjects requiring colonoscopy.
    
  